Abstract
Patients with chronic kidney disease (CKD) often suffer from iron deficiency anemia necessitating treatment with intravenous iron. This study was designed to assess the safety of iron isomaltoside 1000 (Monofer) in CKD patients. The secondary objective was to assess its effect on iron deficiency anemia.
| Original language | English |
|---|---|
| Journal | Indian Journal of Nephrology |
| Volume | 24 |
| Issue number | 5 |
| Pages (from-to) | 589-96 |
| Number of pages | 8 |
| ISSN | 0971-4065 |
| Publication status | Published - 2011 |
Keywords
- Adult
- Aged
- Aged, 80 and over
- Analysis of Variance
- Anemia, Iron-Deficiency
- Biological Markers
- Disaccharides
- Europe
- Female
- Ferric Compounds
- Ferritins
- Hematinics
- Hemoglobins
- Humans
- Infusions, Intravenous
- Injections, Intravenous
- Iron
- Kidney Diseases
- Male
- Middle Aged
- Renal Dialysis
- Time Factors
- Transferrin
- Treatment Outcome
- Young Adult
Fingerprint
Dive into the research topics of 'Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS